Bioventix plc 
                        ("Bioventix" or the "Company") 
                                 Result of AGM 
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting ("AGM"), 
all resolutions put to shareholders were duly passed. 
For further information please contact: 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
About Bioventix plc: 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 

(END) Dow Jones Newswires

December 10, 2020 10:03 ET (15:03 GMT)